Terms: = Thyroid cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
398 results:
1. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
2. The emerging role and clinical significance of circRNAs in papillary thyroid cancer.
Ma J; Xu J; Zhang X; Quan J
Front Endocrinol (Lausanne); 2024; 15():1351776. PubMed ID: 38544689
[TBL] [Abstract] [Full Text] [Related]
3. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
4. GSG2 promotes thyroid cancer via stabilizing AURKB and activating akt pathway.
Zhang F; Huang C
Aging (Albany NY); 2024 Mar; 16(6):5091-5107. PubMed ID: 38441546
[TBL] [Abstract] [Full Text] [Related]
5. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
6. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
7. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/akt/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
8. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
9. A phase 1 study of triple-targeted therapy with BRAF, MEK, and akt inhibitors for patients with BRAF-mutated cancers.
Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of the Therapeutic Effects of Harmine on Anaplastic thyroid cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract] [Full Text] [Related]
11. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract] [Full Text] [Related]
12. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
[TBL] [Abstract] [Full Text] [Related]
13. Network pharmacology to explore the molecular mechanisms of Prunella vulgaris for treating thyroid cancer.
Zhang Z; Zhou J; Guo R; Zhou Q; Wang L; Xiang X; Ge S; Cui Z
Medicine (Baltimore); 2023 Nov; 102(45):e34871. PubMed ID: 37960775
[TBL] [Abstract] [Full Text] [Related]
14. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
[TBL] [Abstract] [Full Text] [Related]
15. USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting PI3K/akt pathway.
Sun J; Xiang Q; Ding D; Yan N
J Bioenerg Biomembr; 2023 Dec; 55(6):457-466. PubMed ID: 37919637
[TBL] [Abstract] [Full Text] [Related]
16. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
17. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies.
Thapa R; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Saleem S; Khan R; Altwaijry N; Dureja H; Singh SK; Dua K
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127375. PubMed ID: 37839597
[TBL] [Abstract] [Full Text] [Related]
18. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
19. TRIP6 disrupts tight junctions to promote metastasis and drug resistance and is a therapeutic target in colorectal cancer.
Gou H; Wong CC; Chen H; Shang H; Su H; Zhai J; Liu W; Liu W; Sun D; Wang X; Yu J
Cancer Lett; 2023 Dec; 578():216438. PubMed ID: 37827326
[TBL] [Abstract] [Full Text] [Related]
20. Study of the PI3K/akt/mTOR signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA-MB-231.
Liu X; Liu J; Yan B; Quan Z; Wang X; Ma Y; Alarfaj AA; Yan L
Environ Toxicol; 2024 Jan; 39(1):444-456. PubMed ID: 37792628
[TBL] [Abstract] [Full Text] [Related]
[Next]
